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A B ST R AC T 
 
 
The metabolic syndrome represents a plethora of cardio-metabolic risk 
factors including obesity, arterial hypertension, atherogenic 
dyslipidemia, hyperglycemia, accompanied by pro-inflammatory and 
pro-thrombotic state. The metabolic syndrome is one of the key risk 
factors for certain types of cancer. Among these malignancies, breast 
cancer and endometrial neoplasms require special attention. 
Incriminated major causes for the development of breast and 
endometrial cancer in metabolic syndrome patients are: the pro-
inflammatory status and related cytokines, adipokine imbalances, 
hyperestrogenism, growth factors, disturbances in cancer 
microenvironment, insulin resistance and hyperinsulinemia. The 
metabolic syndrome consists of molecular dysregulations that create a 
pro-oncogenic status. Our review aims at providing a better 
understanding of the mechanisms underlying the link between the 
metabolic syndrome and endometrial and breast cancer.   
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Introduction  
Breast cancer (BC) ranks the first among solid cancers 
in women, representing a major public health problem 
globally [1], being a major cause of mortality in female 
patients. With this in mind, the identification of modifiable 
risk factors together with the implementation of primary 
prevention methods should be considered a priority [1]. 
There are several studies that investigated the link between 
the metabolic syndrome (MS) and BC with mixed results 
regarding the implication of obesity, high blood pressure 
and dyslipidemia. On the other hand, the association of the 
aforementioned factors proved to increase the risk of 
developing breast neoplasia [2]. Furthermore, endometrial 
cancer (EC) is the most common form of gynecological 
cancer in developed countries [3] and its association with 
obesity, diabetes and hypertension (the endometrial cancer 
triad) is irrefutable. Epidemiological studies have shown a 
2.45-fold higher risk of developing EC in overweight and 
obese patients and 2.12-fold higher in diabetic patients. In 
patients with obesity and hypertension, the risk of 
developing EC is also increased [4]. 
Discussions 
Metabolic syndrome 
The metabolic syndrome represents a group of cardio-
metabolic risk factors including: obesity, arterial 
hypertension, atherogenic dyslipidemia, hyperglycemia 
together with pro-thrombotic and pro-inflammatory states 
[5].  
The World Health Organization’s (WHO) definition of 
MS underwent several adjustments in time. According to 
WHO, MS is characterized by the presence of: glucose 
intolerance, impaired glucose tolerance, or diabetes 
mellitus and/or insulin resistance together with two or more 
of the parameters listed in Table 1 [5]. 
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Table 1. WHO definition of MS (5) 
Parameters Description 
1. High BP ≥140/90 mmHg 
2. High TG  ≥150 mg/dL 
3. Low HDL <35mg/dL in men and 
<39mg/dL in women 
4. Central Obesity  
(Waist-to-Hip ratio)     
or  
BMI ≥30 kg/m2 
>0.9 in men, >0.85 in 
women 





BP- blood pressure, TG- triglycerides, HDL- high 
density lipoprotein, BMI- body mass index 
 
 
Figure 1. Illustration of the metabolic syndrome 
according to WHO (1) 
Endometrial cancer 
Epidemiology 
Endometrial cancer (EC) represents the most common 
gynecological cancer in developed countries, with an 
average incidence of 14.7/ 100,000 among women [3].  
Risk factors 
The risk factors associated with EC are body mass 
index (BMI) ≥ 25, early menarche (before the age 12), 
nulliparity, nulligravidity, the use of oral contraceptives, 
infertility, positive family history of endometrial cancer, 
low level of education. Additionally, there are also studies 
that suggest an association between infertility treatments 
and EC [6]. Regarding the involvement of smoking in the 
development of EC, the results of the studies are 
contradictory. While there are studies that have identified 
an association between cigarette consumption and EC [7], 
there are also studies that support the anti-estrogenic effect 
of smoking [8,9] or studies that have not identified any 
association between smoking and endometrial neoplasia 
[6]. An increased body mass index (BMI) along with 
increased waist circumference values are associated with 
premenopausal uterine neoplasia [10]. High blood pressure 
(HBP) appears to play a role in the development of EC, but 
the underlying mechanism has not been elucidated to this 
day [11,12]. Additionally, diabetes mellitus (DM) and 
hyperinsulinemia have also been identified as risk factors 
for EC [13,14]. 
The metabolic syndrome 
As mentioned above, EC is a type of neoplasm 
commonly associated with obesity, diabetes and 
hypertension (the endometrial cancer triad) [4]. MS is 
involved in the development of EC through the disruption 
of blood glucose homeostasis, serum triglycerides levels, 
insulinemia and insulin-like growth factor (IGF) system 
[14,15].  
Obesity  
The increased risk for developing EC among women 
suffering from obesity is based on the associated 
hyperestrogenism, hyper-insulinemia and insulin 
resistance (IR), lipid metabolism disorders, 
hyperglycemia, chronic inflammation [16]. 
Hyperestrogenism  
A prolonged exposure of the endometrium to the 
endogenous or exogenous estrogens, in the absence of the 
antagonist effect of progesterone, represents the main 
cause of EC. In menopausal women, the adipose tissue, 
through the enzyme aromatase, which converts 
androstenedione into estradiol, is the main source of 
endogenous estrogen [17]. Thus, the serum estradiol 
resulting from this process interacts with endometrial 
estrogen receptors [17].  
Hyperestrogenemia may also be the result of 
hyperinsulinemia, common in obese patients [18]. 
Elevated insulin levels lead to a decrease in sex hormone 
binding protein (SHBP) synthesis and an increased 
bioavailability of insulin-like growth factor 1 (IGF-1) [18]. 
Insulin resistance, in the context of elevated serum levels 
of adipokines (leptin and visfatin) and pro-inflammatory 
cytokines (TNF-α, IL-1β, IL-6, MCP-1), underlies 
hyperinsulinemia, characterized by low serum IGF-1 
binding protein resulting in elevated levels of IGF-1 [19]. 
High levels of insulin and IGF-1 stimulate endometrial 
cancer cell proliferation by binding to insulin receptors 
(IR) and IGF-1 receptors (IGF-1R) [20]. There are studies 
that have demonstrated the synergic effect of insulin and 
estrogen in the stimulation of endometrial tumor cell 
proliferation [21]. 
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Chronic inflammation 
Obesity is characterized by a chronic pro-inflammatory 
status characterized by the infiltration of the adipose tissue 
with macrophages and an increased expression of 
inflammatory cytokines, which represent an important 
factor involved in IR [19]. Studies on human and animal 
subjects with obesity and IR revealed elevated plasma 
levels of C-reactive protein (CRP) and interleukin-6 (IL-6) 
[22].  
Growth factors 
The activity of (VEGF-mTOR)– (the vascular 
endothelial growth factor - mammalian target of 
rapamycin) factor is highly increased in obese women with 
endometrial neoplasm. There are studies proposing VEGF-
mTOR derived from adipocytes as a possible therapeutic 
target in obese women diagnosed with EC [23]. 
Cancer microenvironment  
The adipose tissue can disturb the tumor 
microenvironment by inducing disturbances in the 
extracellular matrix, thus dysregulating the homeostasis of 
the surrounding tissues and creating a favorable status for 
the development of cancer. In addition to the indirect 
effects, adipose tissue also acts directly on neoplastic cells 
through a paracrine mechanism [24]. In addition, there are 
studies that have reported the possibility of a fusion 
capacity between endometrial malignant cells and adipose-
derived stem cells (ASC), with the subsequent expression 
of a fibroblast-like phenotype [25]. All the above are 
associated with a phenomenon of downregulation of E-
cadherin expression and upregulation of Vimentin 
expression [25]. 
Pro-inflammatory cytokines and adipokines  
The roles of cytokines in the regulation of metabolism and 
inter-organ signaling outline the relationship with 
pathophysiology in metabolic disease. Over nutrition along 
with low physical activity (a sedentary lifestyle) has led to an 
increase in metabolic diseases. Several organs and tissues 
(e.g., adipocytes, hepatocytes, muscles, skeleton cells) secrete 
specific cytokines for inter-organ communication, and the 
secretion of these cytokines is modified during nutritional 
stress and physical activity [26,27]. 
 
Table I. A summary of the main cytokines and their effects on glucose and lipid metabolism (decreased glucose 




Adipokines Hepatokines Myokines Osteokines 
TNF-α ↑ Leptin ↑ Fetuin A, B ↑ IL-13 ↓ Osteopontin ↑ 
IL-1β ↑ Adiponectin ↓ Hepassocin ↑ IL-15 ↓ Osteocalcin ↓ 
IL-6 ↑ Resisitin ↑ FGF21  ↑ BDNF ↓ FGF23 ↑ 
MCP-1 ↑ Asprosin ↑ Selenoprotein P ↑ Irisin ↓ Sclerostin ↑ 
TNF-α: tumor necrosis factor; IL: interleukins; MCP-1: Monocyte Chemotactic Protein 1; FGF21: fibroblast growth 
factor 21; FGF23: fibroblast growth factor 23; BDNF: Brain-Derived Neurotrophic Factor.  
Adiponectin, visfatin and leptin are adipokines 
involved in the development and progression of EC [16]. 
Obesity, hypertension, insulin resistance and 
hyperinsulinemia are associated with low serum 
adiponectin [28], which is further correlated with the risk 
of developing EC in postmenopausal women who have not 
received hormone replacement therapy (HRT) [28]. 
Adiponectin is a cytokine secreted by adipocytes and with 
low circulating levels in patients diagnosed with EC [29]. 
Adiponectin exerts its effects through its receptors: the 
adiponectin receptor-1 (AdipoR1) and the adiponectin 
receptor-2 (AdipoR2) [30]. An increase in AdipoR1 
expression compared to the expression of AdipoR2 was 
identified in EC. AdipoR1 plays a role in the inhibition of 
neoplastic cell proliferation, intercellular adhesion and the 
invasiveness of EC [31] and increases cancer cell insulin 
sensitivity [32]. Moreover, adiponectin also has an effect 
on the tumor microenvironment [33]. Thus, the low serum 
level of adiponectin, found among obese people, is closely 
related to the risk of developing endometrial neoplasm 
[34]. 
Visfatin (Visf) is an insulin-like adipokine. Elevated 
serum levels of Visf were found in patients diagnosed with 
EC [35], and its serum level increases with the patients’ 
BMI [36,37]. Given that the ratio of Visf:Adipo is elevated 
in EC, studies have shown that a high serum level of Visf 
represents an independent risk factor for EC [38]. 
Moreover, the Visf level is associated with the risk of 
myometrial invasion, lymph node metastases and a poor 
prognosis for patients diagnosed with EC [36,37]. 
Leptin (Lept) represents another adipokine which is 
involved not only in the development of endometrial, but 
also in breast and colon neoplasm pathogenesis. By 
interacting with the leptin receptor (ObR), it plays an 
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important role in regulating food intake, energy 
consumption and cell growth [39,40]. Zhou et al. 
demonstrated that the serum level of Lept, together with 
the expression ObR, is strongly correlated with the degree 
of EC differentiation.  
Thus, ObRs are intensely expressed in poorly 
differentiated tumors [41]. Additionally, the serum level of 
Lept is an independent risk factor for EC [42]. The cells’ 
malignant transformation, their proliferation and invasion 
capacities are based on the Lept over-activation of the 
PI3K / Akt [42], JNK, STAT3, ERK1 / 2 signaling 
pathways [43,44]. 
Inflammation plays a crucial role in tumorigenesis. In 
patients suffering from obesity, the adipose tissue 
represents the site of a marked inflammatory process 
responsible for systemic metabolic alterations and tumor 
microenvironment disturbances [16]. 
Interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-
α) and plasminogen activator inhibitor-1 (PAI-1) are pro-
inflammatory cytokines involved in tumorigenesis in obese 
people [16]. 
IL-6 is an inflammatory cytokine, associated with an 
increased risk of mortality in overweight/obese people 
[45]. Elevated IL-6 levels represent a predictive factor for 
poor prognosis in cancer patients [46]. Moreover, 
estrogen hormones promote cellular IL-6 expression in 
EC [47]. 
In turn, IL-6 supports the synthesis of aromatase, thus 
accelerating the synthesis of estrogen and creating a 
positive feedback mechanism [48]. The IL-6 / JAK / 
STAT3 signaling pathway is also involved in the 
development of neoplasms. IL-6 causes the hyper-
activation of the aforementioned pathway, which is 
associated with an unfavorable prognosis in cancer 
patients [49]. Additionally, there are studies that 
confirmed that by blocking the IL-6 inflammatory signal, 
the spread of neoplastic cells to the liver may be inhibited 
[49,50]. 
TNF-α is an endogenous tumor-promoting factor 
secreted by macrophages and adipocytes, involved in the 
proliferation, invasion and metastasis of tumor cells [51]. 
Adipocytes can stimulate endometrial cell proliferation 
through a paracrine mechanism that appears to be mediated 
by TNF-α [51]. By activating the NF-Κb signaling 
pathway, TNF-α inhibits the apoptosis of the neoplastic 
cells [16]. 
PAI-1 is a protease inhibitor produced in endothelial, 
stromal and adipocyte cells [16]. It plays an important role 
in the invasion and metastasis of tumors associated with 
obesity [52]. The increased expression of PAI-1 in 
endometrial neoplastic cells is associated with a poor 
prognosis, and an increased risk of disease recurrence [53].  
Diabetes mellitus 
Diabetes mellitus (DM) is a well-known risk factor for 
EC [54], and it is associated with increased mortality 
among EC patients [55]. 
Hyperglycemia  
Hyperglycemia acts directly on the signaling pathways 
involved in the rapid proliferation of tumor cells [56]. In 
addition to a rapid source of energy, glycolysis is also 
responsible for the production of a plethora of metabolic 
intermediates, used for the synthesis of macromolecules, 
such as: nucleic acids, fatty acids and proteins, essential in 
supporting the rapid growth of tumors [16]. 
Hyperglycemia supports the proliferation and invasion 
of endometrial neoplastic cells through the promotion of 
VEGF expression, its receptor (VEGFR), and the 
epithelial-mesenchymal transition (EMT) process by 
regulating Erα/GLUT4 (glucose transporter) expression 
[57]. In addition, hyperglycemia supports the proliferation 
of endometrial neoplastic cells by activating STAT3 
expression [58].  
An enzyme involved in glycolysis is isoenzyme M2 of 
pyruvate kinase (PKM2), which not only plays an 
important role in tumorigenesis, but also in the prognosis 
of cancer patients [59]. 
Lactic acid (LA) is a key metabolite in the neoplastic 
cell glycolysis. It supports the transformation of normal 
cells into tumor cells, it has an immunosuppressive effect 
and promotes angiogenesis [60]. Furthermore, LA 
promotes the transition of M1 anti-tumor macrophages into 
M2 macrophages, which represent the predominant 
population of macrophages associated with EC [61]. The 
uptake of pyruvate and LA by cells is achieved through 
monocarboxylate transporter 1 (MCT1), which is an 
independent marker for EC prognosis [62]. 
Hyperinsulinemia and Insulin resistance  
Insulin resistance and hyperinsulinemia play an 
important role in the development of EC. Moreover, 
hyperinsulinemia is an independent risk factor for EC [63]. 
Elevated serum insulin levels together with IGF-1/2 
accelerate the conversion of androstenedione into estrogen 
via aromatase, and also inhibit SHBG synthesis in patients 
with diabetes [16]. Prolonged exposure to estrogen without 
the antagonistic effect of progesterone is a well-known risk 
factor for endometrial dysplasia and malignant 
transformation [64]. Additionally, IR / IGF-1R are 
prognostic factors associated with lymph node invasion 
[65].  
Given the involvement of hyperinsulinemia in the 
development of EC, there are studies that have investigated 
the potential anti-neoplastic effect of metformin. There are 
data in the literature suggesting that the combination 
between metformin with progesterone therapy may have a 
beneficial effect in patients with an unsatisfactory response 
Cancer and metabolic syndrome - The molecular link 
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to progesterone therapy [66]. Conventional doses of 
metformin proved to be effective for hyperglycemia and 
elevated IGF-1 level management in patients with EC [67]. 
A meta-analysis conducted in 2018 failed to prove the 
protective effect of metformin against the development of 
EC, but showed its beneficial effect in terms of survival 
and risk of recurrence [68]. However, there are also studies 
that do not support the beneficial effects of metformin in 
EC management [69]. 
Dyslipidemia  
The association between hyperglycemia, hyperlipemia 
and HBP doubles the risk of developing EC [70]. A positive 
correlation has been identified between the EC patients’ 
BMI and the serum level of palmitic, oleic and stearic acid 
[71]. An elevated plasma level of eicosapentaenoic acid is 
also associated with EC recurrence [72]. Noteworthy is that 
there are studies that have proven the antitumor effect of 
fatostatin, which has inhibitory effects on the proliferation of 
neoplastic endometrial cells and also induces the apoptosis 
of neoplastic cells [73]. 
Weight loss 
Bariatric surgery or weight loss may reduce the risk of 
developing endometrial hyperplasia or EC [74]. Weight 
loss in patients with EC decreased C-peptide, insulin, CRP, 
leptin, IL-1Rα and IL-6 levels and increased SHBG, IGF-
BP1 and adiponectin levels [75]. Therefore, bariatric 
surgery can reduce the risk of developing EC by reducing 
obesity-associated inflammation [16]. 
Breast cancer 
As mentioned above, breast cancer (BC) ranks as the 
first type of cancer among women, representing a major 
public health problem globally. There are several studies 
that have investigated the link between MS and BC. 
Numerous epidemiological studies analyzed the causal 
relationship between the metabolic syndrome or its 
individual components and BC (1). 
Risk factors 
The risk factors for breast cancer are presented in the 
Table 2. 
 
Table 2. Risk factors for breast cancer [76] 
Risk factors Examples mechanism/ higher risk 
Genetic factors BRCA 1/2 The mutations of those genes are associated with an 
increased risk of BC 
HER 2 The overexpression of the HER 2 oncogene is present in 
20% of BC  
EGFR EGFR overexpression is present in more than 30% of 
inflammatory BC 
c-Myc c-Myc overexpression is common in invasive BC 
RAS The H-RAS overexpression is identified in BC and it is 
associated with a reserved prognosis 
Demographic factors Age BC incidence increases with age 
Sex Female sex 
Family history  Positive family history for CS in first-degree relatives is 





Age of the first 
pregnancy 
Represent risk factors for BC 
Hormones Estrogens Both endogenous and exogenous estrogens are risk 
factors for CS 





Represent risk factors for BC 
 
BC- breast cancer 
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The metabolic syndrome and breast cancer 
Numerous epidemiological studies analyzed the 
causal relationship between the metabolic syndrome or 
its individual components and BC. Therefore, several 
studies have revealed a correlation between diabetes and 
breast cancer, while there are inconclusive results 
regarding the role of obesity, high blood pressure and 
dyslipidemia. Although there is a rather weak 
association between the individual components of the 
metabolic syndrome and the development of breast 
cancer, their combination could increase the risk of 
developing breast neoplasia [2]. 
 The relationship between MS and breast cancer was 
investigated in a large population study that included 
94,000 women, which was conducted over a period of 14 
years; during this time, 5.7% of the women developed 
breast cancer [77]. The risk of breast cancer increased with 
the number of MS components, being 45% higher in 
women who had 4 MS components than in those without 
MS [77]. 
Mechanisms 
The metabolic syndrome consists in certain endocrine, 
metabolic and physiological immunological disturbances 
that can disrupt the molecular pathways involved in the 
pathogenesis of BC. 
Aromatase 
An increased aromatase activity along with an 
increased level of inflammation have been identified in 
the adipose breast tissue of overweight and obese women 
[78]. Aromatase activity is responsible for 
hyperestrogenemia in obese patients (79). Low plasma 
SHBG levels are associated with IR and other 
components of the metabolic syndrome [79]. It is well 
known that estrogen plays an important role in hormone-
dependent breast cancer.  
Adipokines 
The disturbances in the adipokines secretion are also 
involved in the pathogenesis of BC. Increased levels of 
leptin and decreased levels of adiponectin were found in 
obese patients. Leptin stimulates breast cell proliferation 
while adiponectin has a protective effect by inhibiting 
uncontrolled cell growth [2]. 
Insulin resistance and diabetes mellitus  
IR has an important pathogenetic role in BC. 
Hyperinsulinism represents a compensatory mechanism 
for IR, with the consequent binding of insulin to specific 
receptors in breast epithelial cells, leading to the activation 
of the IGF 1 signaling pathway, a pathway known to be 
involved in carcinogenesis. In addition, hyperinsulinism 
may contribute to the development of breast cancer by 
stimulating hepatic IGF-1 production [80]. 
Agnoli et al. demonstrated the link between MS and BC 
in a multicenter study and identified the presence of altered 
fasting blood glucose in patients with MS and BC [81]. 
Chronic inflammation 
 Another important feature of MS with implications in 
tumorigenesis is the chronic inflammation present in these 
patients, expressed through the secretion of cytokines such 
as interleukin-6 and tumor necrosis factor alpha that 
support EC progression [82]. 
The metabolic syndrome and various types of breast 
cancer 
Four subtypes of BC have been described, each one of 
them being different in terms of prognosis, treatment 
options, the presence of estrogen and progesterone 
hormone receptors, HER2 expression and ki-67 
proliferation index [77]. There are several studies in the 
literature that took into consideration the aforementioned 
subtypes of BC and showed that the association between 
breast cancer and the metabolic syndrome is significant 
only for ER positive BCs [77]. Given the pathogenetic 
mechanisms described above, in particular the role of 
estrogen, the risk is expected to be higher for hormone-
dependent tumors. 
Another study investigated the link between MS and 
triple negative BC [83]. The authors reported a higher 
prevalence of MS in triple negative cancer patients (58% 
compared to 37% for other cancers), but without a well-
established causal relationship [83]. 
The metabolic syndrome and the therapeutic response 
in breast cancer 
The potential implications of MS in the treatment 
outcomes of BC patients were also investigated. 
Noteworthy is the association of MS with a high 
cardiovascular risk and the cardiotoxicity of certain 
oncological treatments for breast cancer (especially 
anthracycline-based chemotherapy and anti-HER2 
monoclonal antibodies). A higher risk of cardiotoxicity 
was demonstrated in overweight and obese patients [84]. 
A low adiponectin production in obese people might 
represent the explanation for the adverse cardiovascular 
effects of oncological therapy in obese patients. Animal 
studies have shown an exacerbation of myocardial 
dysfunction after the injection of doxorubicin in mice 
with adiponectin depletion and an improvement in 
cardiac dysfunction induced by doxorubicin 
administration after the exogenous injection of 
adiponectin [85]. 
Preliminary data 
The link between MS and cancer is clearly 
established. There are several meta-analyses in the 
scientific literature that showed a significant increase in 
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the incidence of BC in women suffering from MS. At the 
same time, the authors noted a higher risk in 
postmenopausal women, thus suggesting the different 
pathophysiology behind the genesis of pre- and post-
menopausal BC [2,86].  
Recent data, from a recent meta-analysis of 17 cohort 
observational studies, confirm a strong association 
between the metabolic syndrome and breast cancer (RR 
= 1.15, CI: 1.05-1.26, p = 0.003) [82]. An increased risk 
was also observed among Caucasian women [82].  
The prognostic role of MS in patients with breast 
cancer was also studied in a recent meta-analysis [87] 
that included 9 cohort studies with over 17,000 patients 
diagnosed with BC. The aforementioned study showed 
that the presence of MS was associated with an 
increased risk of breast cancer recurrence ([RR] = 1.52, 
95%, p = 0.02) and overall mortality [87]. The 
conclusion of this meta-analysis was that MS is an 
independent predictive factor for negative prognosis in 
women with BC [87]. The above findings are consistent 
with the results of another study which showed that the 
risk of developing distant metastases is more than 
double in women with BC and MS than in those with 
breast cancer without MS [88]. 
All the above demonstrate that the association 
between cancer and MS represents an intensely debated 
subject with a complicated pathophysiology based on 
multiple, intricate mechanisms. Our paper attempts to 
shed some light over the underlying mechanisms that link 
MS to BC and EC. 
As mentioned above, the main mechanism underlying 
hyperestrogenism in overweight and obese patients is the 
conversion of androgens into estrogens through the action 
of aromatase present in the adipose tissue, thus, 
increasing the circulating estradiol [79], all together with 
the reduced levels of plasma concentration of sex 
hormone transport protein (SHBG) [78]. The activation 
of the signaling pathway is accomplished by binding 
estrogens to ERα receptors, with their consequent 
dimerization, translocation in the nucleus, followed by 
gene transcription and protein synthesis with a role in cell 
proliferation [89]. 
The disruption of adipokine levels cancels the 
protective effect of adiponectin against uncontrolled cell 
growth, while the increased levels of leptin stimulate breast 
cancer cell proliferation [2]. 
Insulin resistance and the consequent hyperinsulinism 
lead to the IGF-1 signaling pathway activation. 
Furthermore, in the context of hyperinsulinemia, the liver 
IGF-1 production is stimulated [81], this being another 
important mechanism involved in BC pathogenesis. 
In addition to the aforementioned pathways involved in 
BC pathophysiology, the chronic inflammatory state that 
defines MS and is characterized by increased levels of pro-
inflammatory cytokines (IL-6 and TNF-alpha) also plays a 
role in breast tumorigenesis [82]. The mechanisms that 
mediate the crosstalk between MS and BC are presented  
in Figure 2. 
 
Figure 2. The major mechanisms linking MS to BC 
pathogenesis. The active adipose tissue disrupts the 
adipokine homeostasis by producing high levels of 
leptin, while the adiponectin levels are decreased, thus 
creating a pro-tumorigenic state. Additionally, the 
chronic pro-inflammatory status, characterized by the 
secretion of inflammatory cytokines (IL-6, TNF-alpha), 
regulates several processes in tumorigenesis. The 
increased adipose tissue aromatase activity is 
responsible for the high circulating estrogens that 
mediate epithelial cell proliferation by interacting with 
the estrogen receptors. Additionally, hyperinsulinism 
stimulates the liver production of IGF-1, its high 
circulating levels increasing the risk of developing 
breast cancer. 
Obesity, diabetes and hypertension represent the 
metabolic triad of EC. Insulin resistance, leptin, lactate 
along with low serum adiponectin and obesity-associated 
chronic inflammation are important factors involved in EC 
occurrence [4]. 
As mentioned above, increased estrogen levels 
represent a risk factor for EC. In overweight and obese 
patients, increased adipose tissue aromatase activity is 
responsible for peripheral estrogen synthesis. 
Hyperestrogenemia may be the result of hyperinsulinemia 
by reducing the synthesis of SHBP [18]. As in the case of 
BC, the chronic inflammation characterized by high levels 
of pro-inflammatory cytokines (IL-6, TNF-alpha, PAI-1) 
supports tumorigenesis in obese female patients [16,22]. 
The adipokines homeostasis is deregulated in MS patients, 
thus, the dysregulation of Visf:Adipo balance, with high 
Visf levels, is associated with EC aggressiveness and a 
poor prognosis [36,37]. 
Hyperglycemia not only disrupts the signaling 
pathways responsible for the rapid cell proliferation in 
cancer (STAT3, PKM2) but it also favors the EMT via 
Erα/GLUT4 [57-59]. Figure 3 exemplifies the underlying 
mechanisms that link MS to EC. 
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Figure 3. The underlying mechanisms that link MS 
to EC 
In overweight/obese patients, the active adipose tissue 
produces high levels of leptin and visfatin, while the 
adiponectin levels are decreased creating a pro-
tumorigenic state. Leptin hyperactivates the PI3K/Akt, 
JNK, STAT3, ERK1/2 signaling pathways, thus 
mediating the malignant transformation of endometrial 
cells and their proliferation. Additionally, there is a 
chronic pro-inflammatory status, characterized by the 
secretion of inflammatory cytokines: IL-6, TNF-alpha 
and PAI-1. The hyperactivation of IL-6/JAK/STAT3 
signaling pathway regulates tumorigenesis, being 
associated with poor prognosis. The increased adipose 
tissue aromatase activity is responsible for the high 
circulating estrogens that mediate epithelial cell 
proliferation by interacting with estrogen receptors. The 
aromatase activity is accelerated by IGF-1/2, which also 
inhibits the synthesis of SHBP in patients with diabetes 
mellitus. The invasive phenotype of endometrial cancer 
cells is supported through the activation of VEGF-
mTOR pathway. Additionally, hyperinsulinism 
stimulates the liver production of IGF-1, its high 
circulating levels increasing the risk of developing 
breast cancer. Hyperglycemia is responsible for cancer 
cell proliferation through the overexpression of 
VEGF/VEGFR and STAT3. Regarding the tumor 
microenvironment, the E-cadherin downregulation 
together with vimentin upregulation are associated with 
the epithelial–mesenchymal transition. 
Highlights 
✓ A comprehensive summary of the mechanisms 
underlying the link between the metabolic syndrome 
and endometrial and breast cancer 
✓  The implication of inflammatory changes associated 
with the metabolic syndrome in oncogenesis 
Conclusions 
In conclusion, the metabolic syndrome is a complex 
condition characterized by insulin resistance, 
hyperinsulinemia, impaired glucose tolerance, type II 
diabetes, dyslipidemia and visceral obesity. Most of the 
molecular disturbances induced by MS are involved in the 
development, progression and prognosis of BC and EC. 
More importantly, although the studies of the association 
between the metabolic syndrome and cancer have shown 
contributions of genetic, biological factors (age, gender, 
ethnicity), MS represents an association of modifiable 
factors and this not only highlights the importance of 
improving lifestyle, balanced diet and regular physical 
activity in cancer prevention, but also the importance of 
combining these measures in the management of patients 
diagnosed with this disease, thus, in preventing morbidity 
and mortality in tumors associated with the metabolic 
syndrome.  
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